We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Lab Technology Will Boost Cell Therapy Applications

By LabMedica International staff writers
Posted on 25 Nov 2013
A newly released family of cell culture systems was designed specifically to support and advance the growing field of cell therapy.

The Xuri Cell Expansion System W25 is the first member of GE Healthcare's (Chalfont St. More...
Giles, United Kingdom) new hi-tech cell culture systems to be released for sale.

This system comprises a reliable and intuitive device for expansion of human cell cultures for cellular therapy purposes. It employs single-use, functionally closed disposables to minimize risk of contamination. The Xuri system can accommodate working volumes from as little as one liter—appropriate for growing high-density cell cultures—with room to expand up to 25 liters. The system is based on GE Healthcare's WAVE rocking technology that provides mixing and aeration. The Xuri system is functionally closed, which minimizes the risk of cell contamination while allowing the culture to reach high cell densities.

The Xuri Cell Expansion System W25 is enhanced by sensors to monitor the cell culture environment and is operated via "UNICORN" control software. The system was designed to deliver reliable and accurate performance for research, process development, or manufacturing operations.

Eric Roman, general manager of research and applied markets at GE Healthcare, said, “Through our scale and innovation, we are committed to addressing the significant challenges that remain in moving from highly promising experimental cell therapies to widely available and affordable treatments. We have an extensive research program, working with leaders in the field such as the Karolinska University Hospital, (Stockholm, Sweden) to develop tailored technologies and workflows. The focus of our Xuri technology family is to enable the safe, reliable, and efficient progress of cell therapies from clinical development to commercialization.”

Related Links:

GE Healthcare
Karolinska University Hospital



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.